The new office is expected to allow MDS Pharma Services to better serve the Japanese pharmaceutical and biotechnology markets, and further enable growth opportunities both in Japan and in the broader Asia-Pacific region.
The new office joins an extensive network of MDS Pharma Services locations in the region, including global central lab facilities in Singapore and Beijing, discovery and preclinical operations in Taiwan, and late stage clinical trial monitoring offices in Beijing, Malaysia and Australia.